Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Dec;16(1):2497902.
doi: 10.1080/21505594.2025.2497902. Epub 2025 May 2.

Lenacapavir's success: Revitalizing antiviral drug discovery

Daniel Miranda Jr  1 , David Jesse Sanchez  1
Affiliations
Editorial

Lenacapavir's success: Revitalizing antiviral drug discovery

Daniel Miranda Jr et al. Virulence. 2025 Dec.
No abstract available

Keywords: HIV; antiviral; capsid inhibitor; drug discovery; drug target; lenacapavir.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Figure 1.
Figure 1.
Drug development over time across the HIV proteome.
See this image and copyright information in PMC

References

    1. Cohen J. The long shot. Science. 2024;386(6727):1208–4. doi: 10.1126/science.adv2100 - DOI - PubMed
    1. Bekker LG, Das M, Abdool Karim Q, et al. Twice-yearly lenacapavir or daily F/TAF for HIV prevention in cisgender women. N Engl J Med. 2024;391(13):1179–1192. doi: 10.1056/NEJMoa2407001 - DOI - PubMed
    1. Kelley CF, Acevedo-Quiñones M, Agwu AL, et al. Twice-yearly lenacapavir for HIV prevention in men and gender-diverse persons. N Engl J Med. 2024;392(13): 1261–1276. - PubMed
    1. Ogbuagu O, Segal-Maurer S, Ratanasuwan W, et al. Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial. Lancet HIV. 2023;10(8):e497–e505. doi: 10.1016/S2352-3018(23)00113-3 - DOI - PubMed
    1. Segal-Maurer S, DeJesus E, Stellbrink H-J, et al. Capsid inhibition with Lenacapavir in multidrug-resistant HIV-1 infection. N Engl J Med. 2022;386(19):1793–1803. doi: 10.1056/NEJMoa2115542 - DOI - PubMed

Publication types

LinkOut - more resources